A company expected to fare well during this time is Eli Lilly, with revenue forecast to improve by 165% in 2030. This will largely be driven by the company’s glucagon like peptide-1 receptor agonist ...

Pfizer has terminated a Phase II study of its CD47 immune checkpoint inhibitor, maplirpacept, due to low recruitment. In an ...

From cancer immunotherapy to diabetes and weight loss breakthroughs, 2025’s top-selling drugs highlight how pharmaceutical ...

The UK’s medical research charity LifeArc has received a windfall of nearly $1.3 billion after selling a portion of its royalty interest in Merck & Co’s blockbuster cancer drug Keytruda to a ...

Its Herceptin biosimilar nearing launch, Celltrion begins work on Keytruda copySouth Korea’s Celltrion has started work on a biosimilar version of pembrolizumab, Merck & Co’s blockbuster ...

As drug development increasingly targets multiple indications, pharma companies must make strategic branding ...

Johnson & Johnson is a pharmaceutical and medical device company. Its two primary business segments are Innovative Medicine, which develops and markets prescription drugs, and MedTech, which ...

What Triggered the Stock Surge: The company expanded rapidly into weight loss programs, launching GLP-1 medication access and ...

Centene's Guidance Withdrawal Spooks Sector, Oscar Health Stock Falls Trump-Administration's Health Agency Overstepped Authority, Reorganization Unlawful: Court Obama Warns 16 Million Americans ...